{
    "clinical_study": {
        "@rank": "79146", 
        "brief_summary": {
            "textblock": "To restore immunologic function and virus-free state in HIV-infected patients. Based on\n      previous studies showing temporary improvement in immune function in HIV-infected patients\n      using peripheral lymphocyte transfers and bone marrow transplantation, and based on studies\n      documenting the antiretroviral effects of zidovudine (AZT) and interferon-alfa (IFN-A) as\n      well as the preliminary test tube and patient studies suggesting anti-HIV effects of\n      recombinant CD4-IgG, we propose to treat HIV-infected patients using combination\n      antiretroviral therapy with transplantation of bone marrow and peripheral lymphocytes from\n      previously immunized donors in an attempt to restore immunologic function and a virus-free\n      state."
        }, 
        "brief_title": "An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection", 
        "completion_date": {
            "#text": "December 1994", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Based on previous studies showing temporary improvement in immune function in HIV-infected\n      patients using peripheral lymphocyte transfers and bone marrow transplantation, and based on\n      studies documenting the antiretroviral effects of zidovudine (AZT) and interferon-alfa\n      (IFN-A) as well as the preliminary test tube and patient studies suggesting anti-HIV effects\n      of recombinant CD4-IgG, we propose to treat HIV-infected patients using combination\n      antiretroviral therapy with transplantation of bone marrow and peripheral lymphocytes from\n      previously immunized donors in an attempt to restore immunologic function and a virus-free\n      state.\n\n      Three patients are treated with stable doses of AZT, IFN-A, and CD4-IgG for 12 weeks,\n      followed by six peripheral lymphocyte infusions and transplantation of bone marrow from\n      their respective identical twins. Following bone marrow transplantation, patients continue\n      to receive the three drugs.  Additional periods of lymphocyte apheresis and transfer may be\n      offered to each donor/recipient pair."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Each patient must have an identical twin in a normal state of health with a normal\n             screening lab panel and a normal immune profile who is documented to be antibody and\n             culture and polymerase chain reaction (PCR) negative for HIV.\n\n          -  Ability to provide informed consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Malignancy other than Kaposi's sarcoma.\n\n        Patients with the following are excluded:\n\n          -  Unwillingness to comply with current NIH Clinical Center guidelines concerning\n             appropriate notification of all current sexual partners of an individual regarding\n             his or her positive HIV serostatus and the risk of transmission of HIV infection.\n\n          -  Presence of a serious opportunistic infection or other illness or condition that, in\n             the opinion of the principal investigator, warrants exclusion from participation in\n             the study.\n\n        Current use of illicit drugs or significant amounts of alcohol that, in the opinion of the\n        principal investigator, would interfere with compliance with the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "6", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000647", 
            "org_study_id": "IRP 011", 
            "secondary_id": [
                "11723", 
                "90 I-0076", 
                "NIAID 90 CC-IRP011"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "CD4-IgG", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Interferon alfa-n1", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Peripheral lymphocyte infusion", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "Bone marrow transplant", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Zidovudine", 
                "Immunoglobulin G", 
                "CD4 Immunoadhesins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Recombinant Proteins", 
            "IgG", 
            "Drug Evaluation", 
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "Antigens, CD4", 
            "Zidovudine", 
            "Carrier Proteins", 
            "Interferon Type I"
        ], 
        "lastchanged_date": "May 17, 2012", 
        "link": {
            "description": "Click here for more information about Zidovudine", 
            "url": "http://aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "Natl Inst of Allergy & Infect Dis / Cln Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection", 
        "overall_official": {
            "last_name": "KM Zunich", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Zunich KM, Easter M, Owen C, Walker R, Davey R, Wilson W, Leitman S, Fauci AS, Lane HC. Bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes from gp160-immunized syngeneic donors combined with zidovudine, interferon-alpha, and recombinant CD4-IgG in the treatment of HIV infection. Int Conf AIDS. 1991 Jun 16-21;7(2):77 (abstract no THB82)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000647"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Natl Inst of Allergy & Infect Dis / Cln Ctr": "38.985 -77.095"
    }
}